Molecular pathology of lung cancer: clinical aspects

Discovery of tyrosine kinase inhibitor sensitizing mutations in lung cancer (LC) appears to be the main event in clinical oncology of the last decade. Activating lesions in epidermal growth factor receptor (EGFR) gene almost guarantee tumor response to gefitinib, erlotinib or afatinib.ALK translocat...

Full description

Saved in:
Bibliographic Details
Main Authors: I. S. Polyakov, E. N. Imyanitov
Format: Artigo
Language:Russo
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2016-02-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
lung cancer
mutations
targeted therapy
Online Access:https://www.siboncoj.ru/jour/article/view/255
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items